Key Points
- Ra Capital Management bought 6,552 more shares of Artiva Biotherapeutics on July 13 at $8.94 each, bringing its direct stake to 16.8 million shares valued at about $150.3 million.
- The firm has been steadily adding to its ARTV position in recent weeks, including a much larger purchase of 6.51 million shares on May 11 and multiple buys in June and July.
- Artiva Biotherapeutics shares traded at $9.35, while analysts maintain a Moderate Buy consensus with a $39 average price target despite the company posting a wider-than-expected quarterly loss.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) Director Ra Capital Management, L.P. acquired 6,552 shares of the company's stock in a transaction that occurred on Monday, July 13th. The stock was bought at an average price of $8.94 per share, with a total value of $58,574.88. Following the transaction, the director directly owned 16,817,573 shares in the company, valued at $150,349,102.62. The trade was a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.97 per share, for a total transaction of $135,464.94.
- On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.98 per share, with a total value of $16,846.48.
- On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.88 per share, with a total value of $275,280.00.
- On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.89 per share, with a total value of $1,110,298.77.
- On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.99 per share, for a total transaction of $138,571.86.
- On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.57 per share, for a total transaction of $3,351,032.83.
- On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $7.91 per share, with a total value of $4,339,267.80.
- On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.00 per share, with a total value of $721.00.
- On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
- On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, for a total transaction of $74,999,992.32.
Artiva Biotherapeutics Price Performance
Shares of NASDAQ:ARTV opened at $9.35 on Wednesday. The stock has a market cap of $231.13 million, a price-to-earnings ratio of -2.64 and a beta of 2.18. The company has a 50 day moving average of $9.01 and a 200-day moving average of $7.02. Artiva Biotherapeutics, Inc. has a one year low of $2.04 and a one year high of $14.53.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.07). Equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in ARTV. Bank of America Corp DE boosted its position in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $41,000. Dimensional Fund Advisors LP acquired a new stake in shares of Artiva Biotherapeutics in the first quarter valued at approximately $131,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics in the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth $139,000.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Needham & Company LLC reissued a "buy" rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an "outperform" rating in a report on Monday, May 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, HC Wainwright boosted their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.
Get Our Latest Stock Report on Artiva Biotherapeutics
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
